MyHealthChecked (LONL MHC) shares are rising on Wednesday after achieving ISO 15189:2012 accreditation across the Company's COVID-19 testing service.
The accreditation was granted following assessments by the United Kingdon Accreditation Service (UKAS), ensuring that the laboratories used as part of the company's COVID-19 testing service deliver high-quality service and meet the relevant legal requirements.
Penny McCormick, CEO of MyHealthChecked, said: “We are delighted to now have in place accreditation across our COVID-19 testing service, which is a clear sign to our existing customers and potential new customers that our medical laboratories and operational systems are extremely rigorous and structured around best possible practice within the industry.
“I am incredibly proud of the MyHealthChecked team for maintaining these high standards, ensuring that we offer a reliable and efficient service to all of our partners.”
MyHealthChecked's share price has moved 3.29% above Tuesday's close, to 3.92p.
Should you invest in MyHealthChecked shares?
MyHealthChecked shares are traded on the London stock exchange's AIM market (the alternative investment market), which is the submarket specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are MHC shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies
